Biohaven

Biohaven Retained Earnings

The Retained Earnings of Biohaven (BHVN) as of Nov 11, 2026 is -2.08 B USD. In the previous year, Retained Earnings was -1.35 B USD — a change of 54.90% (lower).

Retained Earnings

-2.08 BUSD

YoY

54.90%

Last updated:

Retained Earnings of Biohaven is 2025 -2.08 B USD. Retained Earnings of Biohaven was 2024 -1.35 B USD. It decreases by 54.90% lower compared to the previous year.

The Biohaven Retained Earnings history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Retained Earnings
Date
Retained Earnings
Jan 1, 2018
-443.57 M USD
Jan 1, 2019
-972.37 M USD
Jan 1, 2020
-1.74 B USD
Jan 1, 2021
-2.59 B USD
Jan 1, 2022
-91.12 M USD
Jan 1, 2023
-499.29 M USD
Jan 1, 2024
-1.35 B USD
Jan 1, 2025
-2.08 B USD
The Biohaven Retained Earnings history
YEARRetained EarningsYoY
-2.08 BUSD+54.90%
-1.35 BUSD+169.52%
-499.29 MUSD+447.93%
-91.12 MUSD-96.48%
-2.59 BUSD+48.68%
-1.74 BUSD+78.86%
-972.37 MUSD+119.22%
-443.57 MUSD+118.89%
-202.65 MUSD+168.41%
-75.50 MUSD+539.83%
-11.80 MUSD+594.12%
-1.70 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biohaven Stock analysis

What does Biohaven do? Biohaven Pharmaceutical Holding Co. Ltd. generates revenue through the research and development of late-stage product candidates targeting neurological diseases and rare disorders. The company utilizes its glutamate platform to advance clinical-stage compounds for various indications, including trigriluzole for obsessive-compulsive disorder, spinocerebellar ataxia, and Alzheimer's disease. Additionally, the firm develops BHV-0223 for amyotrophic lateral sclerosis and BHV-5000 for conditions such as Rett syndrome, neuropathic pain, and treatment-resistant depression. The business model focuses on identifying and developing clinical-stage compounds that target orphan neurologic indications and other neurological pathways, with the company currently employing 825 full-time employees in New Haven, Connecticut. Biohaven is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biohaven stock

Retained Earnings of Biohaven is -2.08 B USD in 2025.

Retained Earnings of Biohaven changed from -1.35 B USD to -2.08 B USD, representing a 54.90% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Retained Earnings Biohaven since 2006 – with annual values, charts, and detailed analysis.

Retained earnings are the cumulative net income kept in the business rather than paid out as dividends. They fund future growth and operations.

Retained Earnings's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Retained Earnings's Biohaven historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Biohaven

All Key Metrics — Biohaven